Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DUART
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
- 22 Nov 2016 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.
- 22 Nov 2016 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.